Every 8-K that Mural Oncology plc (MURA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MURA filings page.
Mural Oncology reported that shareholders approved the company’s acquisition by XOMA Royalty via a court‑sanctioned Irish scheme of arrangement. At the Scheme Meeting, Proposal 1 passed with 10,103,706 for, 81,149 against and 52,031 abstaining, satisfying the required majority in number and at least 75% of the value of shares voted.
At the Extraordinary General Meeting, shareholders approved the Scheme (Proposal 1) with 10,607,228 for, 89,435 against and 13,056 abstaining, and approved an articles amendment (Proposal 2) with 10,647,967 for, 48,436 against and 13,316 abstaining, ensuring shares issued after the record time are captured by the Scheme or acquired for the scheme consideration. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions and the sanction of the Scheme by the High Court of Ireland.
Mural Oncology plc disclosed a transaction agreement dated August 20, 2025, among Mural Oncology plc, XOMA Royalty Corporation and XRA 5 Corp. The filing describes mutual termination rights: the Company may terminate if the bidder breaches material covenants or if the Board approves a Superior Proposal before shareholder approval; the bidder may terminate for the Companys material breach, a Board change in recommendation, or if the Company solicits a Superior Proposal and does not cure within 15 days.
The filing also includes customary forward-looking disclaimers and lists related exhibits and communications, including a Rule 2.7 announcement, Rule 2.10 letters to shareholders and employees, a directors irrevocable undertaking, and the transaction agreement as exhibits. The disclosures focus on deal mechanics and termination conditions rather than financials.